http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
치아회분과 석고혼합제재 매식과 자가골 동시 이식후 치유과정에 관한 실험적 연구
김영균,김흥중,이상호,여환호,임성철,설인택,정재헌 大韓顎顔面成形再建外科學會 2000 Maxillofacial Plastic Reconstructive Surgery Vol.22 No.1
The purpose of this study was to evaluate the efficacy of adding autogenous bone to the toothash-plaster mixture in the healing process of bone. Full-thickness round osseous defects with the diameter of 20mm were made at the calvarial bone of adult dogs (n=19) bilaterally, which were thought to be critical size defect. The right defects were repaired with the toothash-plaster mixture plus autogenous bone (compressed volume 0.3cc) and the left defects with only toothash-plaster mixture. At 2-, 4-, 8-, 12- and 20- week after implantation, dogs were sacrificed and evaluated the osseous healing of bony defects clinically, radiographically, and microscopically. The results were as follows : 1. At the clinical observation, the wound healed very well without any problem except severe swelling in the early period after operation. Slight depression was recognized at the both sides when the portions of cranial defect were palpated. 2. There were statistically significant differences between toothash-plaster mixture groups and autogenous bone added groups at the same period, and among the groups in the bone density of the digital radiograms (P<0.001).There was a tendency that bone density was increasing with time. 3. In light microscopic examination, new bone formation was more active in the autogenous bone added groups than toothash-plaster mixture groups at the early period after mplantation but there is little difference at 20-week after implantation. 4. In fluorescent microscopic examination, the fluorescent band could be observed at the area of active bone formation and the band was more distinct in the autogenous bone added groups then toothash-plaster mixture groups. 5. In transmitted electron microscopic examination, organelles such as rER, Golgi complex and secretory granule and osteoblast were observed. In summary higher volume ratio of autogenous bone is needed to improve the bone healing in that there is little difference between toothash-plaster mixture group and autogenous bone added group at the 20-week after implantation in spite of new bone formation was more active in the autogenous bone added groups than toothash-plaster mixture groups at the early period after operation.
고영인,임재택,조희숙,황해익,정계숙 부산대학교 영유아보육연구소 1998 영유아보육연구 Vol.4 No.-
The purpose of this study was to investigate longitudinal growth and development of young children and follow-up effects of the educare program in the PNU Day Care Center. Particularly, the first objective of this second report of study was the comparison the entire domains of development with age between the Oct. of 1995 and the Dec. of 1998. The second objective was to analyze the developmental .changes of 5 children who entered the center in 4 years old since Oct. 1995. The subjects of this study were 448 children(241 boys, 207 girls). The instruments of this study were the KISC and KEDl-WISC(for intelligence test), the Learning Readiness Test, the Social and Emotional Scale, Height Scale and Weight Scale( for physical growth). The tests were carried out 2 times per year (the early of the year and the late of the year). Results from comparsion across the 1st through 7th tests during 3 years indicated that the mean of the height was increased about 1-8cm for all of 2-5 years old children. The mean of the weight also was increased about 1.5-4.0kg except 2 years old children. The intelligence score (T score) by KISC was increased around 6-42 points except 6 years old boys and girls. In the intelligence score by KEDl, there was improvements of average 8 points for 7 years old children. In the learning Readiness Test of 5, 6 years old children, the scores all of children except 6 years old girls got were decreased. The scores of 6 years old girls were incresed 6 points in the Dec. of 1998. In the Social and Emotional Scale, there was big improvement of scores between in the 1st test and in the 7th test. These results were discussed in the view of sample size, developmental characteristics, test instruments and educare program of the PNU day care center.
( Young-Suk Lim ),( Sang Hoon Ahn ),( Kwan Sik Lee ),( Seung Woon Paik ),( Youn-Jae Lee ),( Sook-Hyang Jeong ),( Ju-Hyun Kim ),( Seung Kew Yoon ),( Hyung Joon Yim ),( Won Young Tak ),( Sang-Young Han 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Background: Similar to the United States and Europe, the majorityof patients with chronic HCV infection in Japan, Korea, and Taiwanare infected with HCV genotype (GT) 1. However, important differencesin viral and host characteristics exist between the infected populationsin these regions, including age, BMI, IL28B genotype andHCV GT1 subtype. The aim of this integrated analysis is to evaluatethe efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) in a largecohort of Asian patients with chronic GT1 HCV infection.Methods: This analysis combines data from subjects enrolled in twoPhase 3 trials: GS-US-337-0113 (Japan) and GS-US-337-0131 (Koreaand Taiwan) evaluating 12 weeks of LDV/SOF (90mg/400mg) in treatment-naive and treatment-experienced adults with chronic GT1 HCVinfection. The primary efficacy endpoint was SVR12.Results: Overall, 349 subjects were enrolled in Korea, Taiwan, andJapan, 67 (19%) had cirrhosis. The majority were female (58%), treatment-experienced (51%), GT1b infected (94%), and IL28B CC (62%).The mean age (range) was 57 (18-80) years old, BMI 24 (17-38)kg/m2, and HCV RNA was 6.6 (3.7-7.6) log10 IU/mL. HCV NS5ARAVs were detected in 23% (80/343) of subjects at baseline. Theoverall SVR12 rate was 99% (346/349); 2 subjects relapsed and 1subject prematurely discontinued treatment. All treatment-experiencedsubjects with cirrhosis (45/45) achieved SVR12. NS5A RAVswere detected at the time of relapse but no NS5B RAVs were detected.Serious AE and treatment discontinuations were rare (<2%). Adverseevents were generally mild in severity. No significant laboratory abnormalitieswere observed.Conclusions: A single tablet regimen of LDV/SOF administered oncedaily for 12 weeks is highly effective and well tolerated in Asianpatients with chronic GT1 HCV infection, including those with compensatedcirrhosis. Prior HCV treatment experience
( Young-Suk Lim ),( Si-Hyun Bae ),( Sang Hoon Ahn ),( Hyung Joon Kim ),( Won Young Tak ),( Kwan Sik Lee ),( Maria Buti ),( Edward Gane ),( Wai Kay Seto ),( Henry LY Chan ),( Wan-Long Chuang ),( Tatjan 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV),is more stable in plasma and enhances delivery of TFV into hepatocytes while lowering circulating levels of TFV by approximately 90% compared to tenofovir disoproxil fumarate (TDF). Methods: In this Phase 3 study, patients with HBeAg-negative chronic hepatitis B (CHB) were randomized 2:1 to TAF 25 mg QD or TDF 300 mg QD and treated for 96 weeks. After Week 96, patients receive open label TAF for 48 weeks. The primary efficacy analysis was the percent of patients with HBV DNA <29 IU/mL at Week 48. Key secondary safety endpoints were assessed sequentially: changes in hip and spine bone mineral density (BMD), changes in serum creatinine (sCr), and dipstick proteinuria. Markers of bone formation and resorption, and renal tubular function were also assessed. Results: 425 patients were randomized and treated at 105 sites in 17 countries. Baseline characteristics included: mean age 46 years, 61% males, 72% Asians; 19% had HBV DNA ≥ 7 log10 IU/mL, and 21% were previously treated with nucleos(t)ides. At Week 48, TAF was non-inferior in efficacy to TDF with virologic response of 94.0% with TAF and 92.9% with TDF. A greater percentage of patients treated with TAF also achieved normalization of serum ALT values. Patients on TAF experienced significantly less declines in hip and spine BMD than TDF. No differences were seen in sCr change and proteinuria; however, smaller declines in eGFRCG and smaller changes in renal tubular markers were observed in the TAF arm. No viral resistance was observed in the 4 patients (2 per group) who qualified for testing. Conclusions: Compared to TDF 300 mg, the efficacy of TAF 25 mg in patients with HBeAg-negative CHB was noninferior. Safety was also improved, with less change in bone and renal parameters.
TAK, EUNYOUNG,HWANG, SHIN,LEE, HAN CHU,KO, GI-YOUNG,AHN, CHUL-SOO,YOON, YOUNG-IN,LIM, YOUNG-SUK,JUN, DAE-YOUNG,KIM, KI-HUN,SONG, GI-WON,MOON, DEOG-BOK,RYOO, BAEK-YEOL,KIM, NAYOUNG,LEE, SUNG-GYU Potamitis Press 2016 Anticancer research Vol.36 No.11
<P>Background/Aim: We investigated the expression of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) and HBV X protein (HBx) in human hepatocellular carcinoma (HCC) and evaluated the effect of high-concentration nucleos(t)ide analogs (NUCs) on liver tumor cell lines. Materials and Methods: This study consisted of three parts: part I used human blood and non-tumor liver tissues; part II used human HCC and adjacent liver tissues; and part III used an HBV-expressing liver tumor cell line. Results: There were close correlations among blood and liver HBV DNA and liver cccDNA. HBV cccDNA and HBx were highly up-regulated in HCC compared to adjacent liver tissues despite NUC therapy. HBV cccDNA and HBx were highly up-regulated in the cccDNA-expressing HepG2.2.15 cell line. Their expression was down-regulated and apoptosis was induced by a very high concentration of NUCs in dose-and time-dependent manner. Conclusion: Very high concentrations of NUCs may have a novel potential to kill replicating HBV-expressing liver tumor cells.</P>
( Young-Suk Lim ),( Hyung Joon Kim ),( Ki Tae Yoon ),( Won Young Tak ),( Jae-Seok Hwang ),( Sang Hoon Ahn ),( Kwan Soo Byun ),( Seung Woon Paik ),( Sook-Hyang Jeong ),( Yoon Jun Kim ),( So Young Kwon 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: TAF has shown similar efficacy to TDF with less bone and renal effects in 2 large multinational Phase 3 studies after 96weeks(2 years) of double-blind (DB) treatment. Here we evaluated efficacy and safety, including bone and renal parameters, in the subset of patients from East Asia(EA) who completed 2years of DB treatment with TAF 25mg or TDF 300mg once daily and were switched to open label(OL) TAF 25mg once daily for 1year. Methods: In 2 identically-designed studies, 1298 CHB patients who were HBeAgnegative (Study 108; N=425) or HBeAgpositive(Study 110; N=873) were randomized and treated. At Week96, 540(42%; TAF 360; TDF 180) patients including 240(18%; TAF 156; TDF 84) EA patients, had completed 2years of DB TAF or TDF treatment and been switched to OL TAF. Safety including bone(serial DXA scans of spine and hip) and renal(CrCl by Cockcroft-Gault [eGFR<sub>CG</sub>]) parameters, viral suppression and biochemical response were assessed at Year 3. Results: In EA patients on DB TDF switched to OL TAF(TDF<sup>®</sup>TAF), eGFRCG improved at Year 3 vs. Year 2 (median [Q1, Q3] change = +3.0 [-3.0, +8.4] ml/min); and was stable in those continuing TAF(TAF<sup>®</sup>TAF)(figure). BMD also improved at Year 3 vs. Year 2 in TDF<sup>®</sup>TAF patients (mean[SD]% change: spine = +2.2%[3.48]; hiP=+0.7%[2.44]) while BMD changes were stable for TAF<sup>®</sup>TAF patients (figure). High rates of virologic control (HBV DNA<29IU/mL) were maintained in those on treatment at Year3 vs Year2(TDF<sup>®</sup>TAF 96% and 95% and TAF<sup>®</sup>TAF 90% and 93%); ALT normalization (AASLD criteria) increased in TDF<sup>®</sup>TAF patients and was similar to TAF<sup>®</sup>TAF patients at 1 year following switch(46% vs 42%; M=F). Conclusions: EA patients switched to TAF after 2 years of TDF had improved bone and renal safety; virologic control was maintained and ALT normalization increased. The results in EA patients are comparable to those seen in the overall population.
( Young-Suk Lim ),( Hyung Joon Kim ),( Ki Tae Yoon ),( Won Young Tak ),( Jae-Seok Hwang ),( Sang Hoon Ahn ),( Kwan Soo Byun ),( Seung Woon Paik ),( Sook-Hyang Jeong ),( Yoon Jun Kim ),( So Young Kwon 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: In this randomized, double-blind study in HBeAg-positive patients, the efficacy of TAF was demonstrated to be non-inferior to that of TDF at Week48 in the proportion with HBV DNA<29 IU/mL with improved bone and renal effects. Here we present the subgroup efficacy analysis of Korean patients in the study. Methods: In this study, patients with HBeAg-positive CHB were randomized 2:1 to TAF 25mg or TDF 30mg, with matching placebo, and treated for 96weeks. The primary efficacy analysis was the percent of patients with HBV DNA<29 IU/mL at Week48. The results of primary efficacy analysis of Korean patients were separately analyzed. Results: 873 patients were randomized and treated, including 173 subjects(20%) in the Korea population (TAF 120 subjects; TDF 53 subjects). Comparison across the 3 subject populations (Korea, nonKorea, and overall) showed that Korea subjects were older, a higher proportion were female and ≥ 50 years of age at baseline, a lower mean baseline HBV DNA level, and similar portion of treatment-experienced subjects. Nearly all were genotype C. Key efficacy end points are summarized in the Table. The percentages of Korean subjects with HBV DNA levels <29 IU/mL at Week48 were higher than the non-Korea population (74% with TAF and 76% with TDF). Smaller percentage of Korean patients treated with TAF achieved normalization of serum ALT values and HBeAg seroconversion rates were similar(TAF 10%; TDF 9%). The rates of treatment discontinuations and serious AEs were low and similar, consistent with overall population. Korea subjects treated with TAF showed smaller declines in hip and spine BMD and smaller changes in CrCl at Week48 compare with TDF arm. No viral resistance was observed. Conclusions: Compared to TDF 300mg, the efficacy of TAF 25mg in patients with HBeAg-positive CHB was non-inferior. Week48 efficacy results of Korean population were consistent with those of the nonKorea and overall populations.